Gong, Jun

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 259

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation

Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 207